Dactolisib (Tosylate)

• Description :

  Dactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and mTOR kinase inhibitor with IC50 values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2.

• Product Name Alternative :

  BEZ235 (Tosylate) ; NVP-BEZ 235 (Tosylate)

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H312, H332

• Target :

  Autophagy; mTOR; PI3K

• Type :

  Reference compound

• Related Pathways :

  Autophagy; PI3K/Akt/mTOR

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/BEZ235-Tosylate.html

• Purity :

  99.87

• Solubility :

  DMSO : 34 mg/mL (ultrasonic; warming) |H2O : < 0.1 mg/mL

• Smiles :

  CN(C1=C2C3=CC(C4=CC5=CC=CC=C5N=C4)=CC=C3N=C1)C(N2C6=CC=C(C=C6)C(C)(C#N)C)=O.CC7=CC=C(S(=O)(O)=O)C=C7

• Molecular Formula :

  C37H31N5O4S

• Molecular Weight :

  641.74

• Precautions :

  H302, H312, H332

• References & Citations :

  [1]Maira SM, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther, 2008, 7 (7), 1851-1863.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• Isoform :

  MTOR; mTORC1; mTORC2; PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ

• Citation 01 :

  Arch Pharm (Weinheim) . 2024 Sep;357 (9) :e2400066.|J Clin Toxicol 2014, 4:5|J Clin Toxicol. 2014 October 4, 4:5.|Sci Data. 2024 Sep 19;11 (1) :1024.|Actome. 2024.|Adv Sci (Weinh) . 2023 Aug;10 (24) :e2300881.|Adv Sci (Weinh) . 2025 Aug 19:e05656.|Am J Dig Dis (Madison) . 2015;2 (2) :95-99.|Am J Transl Res. 2019 Sep 15;11 (9) :5573-5585.|Anim Cells Syst. 2021 Oct 11;25 (5) :312-322.|Biochem Pharmacol. 2022 Jul:201:115093.|Biomed Res Int. 2018 Aug 5:2018:8372085.|Biomed Res Int. 2021 Apr 16:2021:5556306.|bioRxiv. 2024 September 10.|Blood. 2019 Oct 17;134 (16) :1323-1336. |BMC Med. 2021 Oct 15;19 (1) :247.|Br J Cancer. 2022 Jul;127 (1) :30-42.|Cancer Cell Int. 2023 Sep 27;23 (1) :217.|Cancer Gene Ther. 2021 Apr;28 (3-4) :335-349.|Cancer Res. 2025 Jan 2;85 (1) :32-51.|Cancers (Basel) . 2022 Oct 10;14 (19) :4966.|Cell Commun Signal. 2023 May 24;21 (1) :120.|Cell Death Dis. 2020 Jun 30;11 (6) :491.|Cell Res. 2019 Nov;29 (11) :895-910. |Cell Signal. 2024 Sep 16:111415.|Cell Syst. 2018 Apr 25;6 (4) :424-443.e7.|Cell Syst. 2020 Jan 22;10 (1) :66-81.e11.|Cell. 2025 Dec 11;188 (25) :7155-7174.e25.|EBioMedicine. 2015 Nov 19;2 (12) :1944-56. |Eur J Med Chem. 2023 Oct 5:258:115543.|Exp Hematol Oncol. 2016 Jul 29:5:22.|Exp Mol Pathol. 2025 Jul 24:143:104988.|Front Oncol. 2022 Oct 6:12:1011762.|Front Pharmacol. 2020 Nov 11;11:580407.|Gene. 2025 May 20:950:149369.|Haematologica. 2020 Mar;105 (3) :674-686.|Harvard Medical School LINCS LIBRARY|Int J Med Sci. 2024 Jul 9;21 (10) :1814-1823.|J Biol Chem. 2020 May 22;295 (21) :7431-7441.|J Chemother. 2023 Apr;35 (2) :95-103.|J Exp Clin Cancer Res. 2018 Aug 9;37 (1) :188. |J Mol Cell Cardiol. 2018 May:118:133-146.|J Nanobiotechnology. 2022 Apr 12;20 (1) :187.|J Orthop Surg Res. 2025 Jul 9;20 (1) :631.|JCI Insight. 2022 Aug 22;7 (16) :e155899.|Leukemia. 2014 Sep;28 (9) :1819-27. |Mol Cancer Ther. 2020 Jun;19 (6) :1351-1362.|Molecules. 2019 Apr 1;24 (7) :1260.|Molecules. 2020 Apr 23;25 (8) :1980.|Molecules. 2025 May 27;30 (11) :2347.|Nat Commun. 2017 Jun 8;8:15617.|Nature. 2018 Aug;560 (7719) :499-503.|NPJ Precis Oncol. 2025 Nov 21;9 (1) :373.|Onco Targets Ther. 2020 Apr 30;13:3501-3510. |Oncotarget. 2017 Jul 11;8 (28) :45470-45483. |Oncotarget. 2018 Feb 1;9 (35) :23878-23889.|Oncotargets Ther. 2020 Nov 27;13:12225-12241.|Oxid Med Cell Longev. 2021 Oct 22:2021:5806602.|Patent. US20210236501A1.|Sci Adv. 2023 Mar 22;9 (12) :eadd5028.|Sci Rep. 2024 Oct 28;14 (1) :25815.|Sci Rep. 2019 Oct 22;9 (1) :15099. |Sci Signal. 2021 Jun 22;14 (688) :eabe6156.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|University of North Carolina. School of Medicine, Curriculum in Genetics and Molecular Biology 2021 Aug.

• CAS Number :

  [1028385-32-1]